RxDoctor Payments Data

Matthew Graziano, PA

Medical · Buffalo, NYNPI 1316992985

Payments from drug & device makers

$1,583in general payments, 2019–2025

Across 94 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$488
  • Pfizer$286
  • Esperion Therapeutics, Inc.$205
  • Novartis$108
  • E.r. Squibb & Sons, L.L.C.$106
  • Edwards Lifesciences$69
  • plus $321 from 9 others

What the payments were for

  • Food & beverage$1,56999%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,583 in reported general payments places this provider in the 75th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$17,012
Medicare patients
136
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban969$1,130,898
XareltoRivaroxaban293$388,577
Repatha SureclickEvolocumab240$234,879
EntrestoSacubitril/Valsartan172$207,870
JardianceEmpagliflozin85$80,851
Praluent PenAlirocumab43$40,947
Metoprolol Succinate1,643$39,223
FarxigaDapagliflozin Propanediol32$31,268
Repatha SyringeEvolocumab27$25,226
BrilintaTicagrelor21$24,653
Dabigatran EtexilateDabigatran Etexilate Mesylate51$20,061
Icosapent Ethyl32$14,722
Atorvastatin Calcium816$14,369
Rosuvastatin Calcium646$11,906
Diltiazem 24hr Er (Cd)Diltiazem Hcl189$11,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$286$1,130,898969 claims
Johnson & JohnsonXarelto$49$388,577293 claims
NovartisEntresto$108$207,870172 claims
AstraZenecaFarxiga, Brilinta$14$55,92153 claims
Esperion Therapeutics, Inc.Nexletol$205$10,87211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,395 medical providers in New York.

Other medical in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →